Technical Analysis for ZGNX - Zogenix, Inc.

Grade Last Price % Change Price Change
grade B 41.44 -1.03% -0.43
ZGNX closed down 1.03 percent on Friday, December 14, 2018, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Down
See historical ZGNX trend table...

Date Alert Name Type % Chg
Dec 14 Fell Below 20 DMA Bearish 0.00%
Dec 14 Fell Below 50 DMA Bearish 0.00%
Dec 13 20 DMA Support Bullish -1.03%
Dec 13 50 DMA Support Bullish -1.03%
Dec 12 NR7 Range Contraction -5.73%
Dec 12 Inside Day Range Contraction -5.73%
Dec 12 Up 3 Days in a Row Strength -5.73%
Dec 11 200 DMA Resistance Bearish -5.06%
Dec 11 Upper Bollinger Band Touch Strength -5.06%
Dec 10 50 DMA Support Bullish -3.81%

Older signals for ZGNX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The company's lead product candidate, Zohydro, a single-entity extended-release hydrocodone, which has completed Phase III clinical trials for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. It is also developing Relday, an injectable formulation of risperidone, which is in a Phase I clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. Zogenix, Inc. markets and sells its Sumavel DosePro to wholesale pharmaceutical distributors and retail pharmacies in the United States. It has a licensing and distribution agreement with Desitin Arzneimittel GmbH to develop and commercialize DosePro in the European Union, Norway, Switzerland, and Turkey. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.
Is ZGNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 62.75
52 Week Low 33.42
Average Volume 553,959
200-Day Moving Average 44.5552
50-Day Moving Average 41.6228
20-Day Moving Average 41.891
10-Day Moving Average 42.845
Average True Range 1.9554
ADX 17.43
+DI 20.9283
-DI 21.0704
Chandelier Exit (Long, 3 ATRs ) 39.1038
Chandelier Exit (Short, 3 ATRs ) 44.4362
Upper Bollinger Band 44.5577
Lower Bollinger Band 39.2243
Percent B (%b) 0.42
BandWidth 12.731613
MACD Line 0.212
MACD Signal Line 0.1533
MACD Histogram 0.0587
Fundamentals Value
Market Cap 1.03 Billion
Num Shares 24.8 Million
EPS -3.42
Price-to-Earnings (P/E) Ratio -12.12
Price-to-Sales 35.07
Price-to-Book 12.08
PEG Ratio -0.43
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 44.40
Resistance 3 (R3) 44.55 43.73 43.90
Resistance 2 (R2) 43.73 42.97 43.65 43.74
Resistance 1 (R1) 42.58 42.51 42.17 42.43 43.57
Pivot Point 41.76 41.76 41.55 41.68 41.76
Support 1 (S1) 40.61 41.00 40.20 40.46 39.31
Support 2 (S2) 39.79 40.54 39.71 39.14
Support 3 (S3) 38.64 39.79 38.98
Support 4 (S4) 38.49